Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roh, Sungwon | - |
dc.contributor.author | Lee, Kang Soo | - |
dc.contributor.author | Choi, Songhwa | - |
dc.contributor.author | Kim, Jae-Min | - |
dc.date.accessioned | 2022-09-19T12:14:07Z | - |
dc.date.available | 2022-09-19T12:14:07Z | - |
dc.date.created | 2022-09-08 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171524 | - |
dc.description.abstract | Objective: Although the safety and efficacy of desvenlafaxine have been demonstrated, long-term evidence in Asians is lacking. We examined the safety and effectiveness of desvenlafaxine for up to 6 months in routine clinical practice in Korea. Methods: This multicenter, open-label, prospective observational study was conducted from February 2014 to February 2020 as a postmarketing surveillance study of desvenlafaxine (ClinicalTrials.gov identifier: NCT02548949). Adult patients with major depressive disorder (MDD) were observed from the initiation of treatment for 8 weeks (acute treatment phase) and then up to 6 months (continuation treatment phase) in a subsample. Safety was evaluated by incidence of adverse events (AE) and adverse drug reactions. Treatment response was assessed using the Clinical Global ImpressionResults: We included 700 and 236 study subjects in the analysis of acute and continuation treatment phase, respectively. In acute treatment phase, AE incidence was 9.86%, with nausea being most common (2.00%). In continuation treatment phase, AE incidence was 2.97%, with tremor occurring most frequently. After acute treatment (n = 464), the treatment response rate according to the CGI-I score at week 8 was 28.9%. In long-term users (n = 213), the response rate at month 6 was 45.5%. During the study period, no clinically relevant changes in BP were found regardless of concomitant use of antihypertensive drugs. Conclusion: This study provides evidence on the safety and effectiveness of desvenlafaxine in adults with MDD, with a low incidence of AE, consistent AE profile with previous studies, and improved response after long-term treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | - |
dc.title | Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Roh, Sungwon | - |
dc.identifier.doi | 10.9758/cpn.2022.20.3.548 | - |
dc.identifier.scopusid | 2-s2.0-85135764983 | - |
dc.identifier.wosid | 000831692700010 | - |
dc.identifier.bibliographicCitation | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.20, no.3, pp.548 - 559 | - |
dc.relation.isPartOf | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.citation.title | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 548 | - |
dc.citation.endPage | 559 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002871649 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TREATMENT-RESISTANT DEPRESSION | - |
dc.subject.keywordPlus | INTEGRATED ANALYSIS | - |
dc.subject.keywordPlus | 100 MG/DAY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | OUTPATIENTS | - |
dc.subject.keywordPlus | HEALTH | - |
dc.subject.keywordPlus | FOCUS | - |
dc.subject.keywordAuthor | Desvenlafaxine | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.subject.keywordAuthor | Antidepressant | - |
dc.subject.keywordAuthor | Major depressive disorder | - |
dc.subject.keywordAuthor | Korea | - |
dc.identifier.url | https://www.cpn.or.kr/journal/view.html?doi=10.9758/cpn.2022.20.3.548 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.